Pay in 4 interest-free payments of $29.49 Learn more
Ships within 48 hours · Estimated delivery Sep 18 - Sep 23
Formula: C53H74BrN9O9S
and bioavailabilities (F%) of 100 and 80%
122 μM and 0
[Epub ahead of print] PubMed PMID: 26317790
InChiKey: GBJVVSCPOBPEIT-UHFFFAOYSA-N
BI-3406 Size:10mg solid Formula: C53H74BrN9O9SBI 3406 is Potent & Selective SOS1:: KRAS Inhibitor (IC50=5 nM), which Opens a New Approach for Treating KRAS Driven Tumours. BI 3406 selectively binds to SOS1 and blocks the interaction with KRAS, irrespective of the KRAS mutation. BI 3406 causes RAS GTP and pERK reduction and inhibits cell growth of KRAS mutated cell lines, carrying most of the typical KRAS mutations (i. e. G12D, G12V, G13D and others). BI 3406, when administered orally to tumour
US$ 11.75
US$ 12.95
US$ 16.00
US$ 183.00